Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
RUBY's Phase III clinical trial using Jemperli (dostarlimab) and chemotherapy for endometrial cancer has successfully improved patient survival rates
3 November 2023
Clinical trial phase III of RUBY, using Jemperli (dostarlimab) with chemotherapy for treating endometrial cancer, successfully reaches endpoint in enhancing overall patient survival rate.
Drug Insights
4 min read
Loracarbef: Detailed Review of its Transformative R&D Success
3 November 2023
This article summarized the latest R&D progress of Loracarbef, the Mechanism of Action for Loracarbef, and the drug target R&D trends for Loracarbef.
Latest Hotspot
3 min read
NovelMed Initiates Phase II Trial of Anti-Bb Antibody (NM8074) for Untried PNH Patients: An Insight into the PNH Study Development
3 November 2023
NovelMed Therapeutics kicks off its Phase II trial for untreated Paroxysmal Nocturnal Hemoglobinuria (PNH) patients. The primary investigation will be on the anti-Bb antibody NM8074 through a comprehensive study, aiming to evaluate its safety and efficiency in PNH patients.
Drug Insights
4 min read
ExploringEbastine's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
3 November 2023
This article summarized the latest R&D progress of Ebastine, the mechanism of action for Ebastine, and the drug target R&D trends for Ebastine.
Latest Hotspot
3 min read
Novartis's atrasentan trial in Phase III showed effective and notable proteinuria reduction in IgA nephropathy (IgAN) patients with high statistical significance
3 November 2023
Novartis published positive early results from the critical Phase III ALIGN trial midpoint evaluation, studying atrasentan, an oral ERA for treating people with IgA nephropathy.
Bio Sequence
2 min read
Biological Glossary | What is Exon?
3 November 2023
Exons are coding sections of an RNA transcript, or the DNA encoding it, that are translated into protein.
Latest Hotspot
3 min read
Innovent reports significant weight loss, multiple metabolic benefits, and positive safety record with a higher 9mg dose of Mazdutide (IBI362), after a 48-week Phase 2 trial for obesity
3 November 2023
Innovent reports substantial weight reduction, several metabolic advantages, and a good safety record with a higher dose of 9 mg Mazdutide (IBI362) following a 48-week trial in phase 2 study for obesity.
Drug Insights
4 min read
Decoding Etelcalcetide: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
3 November 2023
This article summarized the latest R&D progress of Etelcalcetide, the mechanism of action for Etelcalcetide, and the drug target R&D trends for Etelcalcetide.
Latest Hotspot
3 min read
Germany's Merck KGaA enhances its oncology portfolio by partnering strategically with Hengrui for advanced PARP1 inhibitor and antibody-drug conjugate
3 November 2023
Merck KGaA, Darmstadt, has formed a strategic partnership with Jiangsu Hengrui Pharmaceuticals Co. Ltd. It holds a global exclusive license to develop, manufacture, and distribute Hengrui’s advanced PARP1 trapping inhibitor HRS-1167.
Bio Sequence
2 min read
Biological Glossary | What is Enhancer?
3 November 2023
Enhancers are one type of DNA sequence that has important functions in biology.
Latest Hotspot
4 min read
Coherus and Junshi Biosciences reveal FDA validation for LOQTORZI™ (toripalimab-tpzi) in all treatment phases for repeated or spreading Nasopharyngeal Cancer (NPC)
3 November 2023
Coherus BioSciences, Inc. along with Shanghai Junshi Biosciences Co., Ltd. revealed that the FDA has given its approval for LOQTORZI™ (toripalimab-tpzi) to be used with cisplatin and gemcitabine.
Drug Insights
4 min read
Deep Scientific Insights on Eteplirsen's R&D Progress, Mechanism of Action, and Drug Target
3 November 2023
This article summarized the latest R&D progress of Eteplirsen, the mechanism of action for Eteplirsen, and the drug target R&D trends for Eteplirsen.